Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation

Journal of NeuroVirology - Tập 21 - Trang 508-517 - 2015
Lbachir BenMohamed1,2,3,4, Nelson Osorio5, Ruchi Srivastava1, Arif A. Khan1, Jennifer L. Simpson6, Steven L. Wechsler5,7,8
1Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, USA
2Department of Molecular Biology & Biochemistry, School of Medicine, University of California Irvine, Irvine, USA
3Institute for Immunology, School of Medicine, University of California Irvine, Irvine, USA
4Laboratory of Cellular and Molecular Immunology, Ophthalmology Research Laboratories, Gavin Herbert Eye Institute, Irvine, USA
5Virology Research, Gavin Herbert Eye Institute and Department of Ophthalmology, School of Medicine, University of California, Irvine, Irvine, USA
6Gavin Herbert Eye Institute and Department of Ophthalmology, School of Medicine, University of California Irvine, Irvine, USA
7Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, Irvine, USA
8Center for Virus Research, University of California, Irvine, Irvine, USA

Tóm tắt

Blinding ocular herpetic disease in humans is due to herpes simplex virus type 1 (HSV-1) reactivations from latency, rather than to primary acute infection. The cellular and molecular immune mechanisms that control the HSV-1 latency-reactivation cycle remain to be fully elucidated. The aim of this study was to determine if reactivation of the HSV-1 latency-associated transcript (LAT) deletion mutant (dLAT2903) was impaired in this model, as it is in the rabbit model of induced and spontaneous reactivation and in the trigeminal ganglia (TG) explant-induced reactivation model in mice. The eyes of mice latently infected with wild-type HSV-1 strain McKrae (LAT(+) virus) or dLAT2903 (LAT(−) virus) were irradiated with UV-B, and reactivation was determined. We found that compared to LAT(−) virus, LAT(+) virus reactivated at a higher rate as determined by shedding of virus in tears on days 3 to 7 after UV-B treatment. Thus, the UV-B-induced reactivation mouse model of HSV-1 appears to be a useful small animal model for studying the mechanisms involved in how LAT enhances the HSV-1 reactivation phenotype. The utility of the model for investigating the immune evasion mechanisms regulating the HSV-1 latency/reactivation cycle and for testing the protective efficacy of candidate therapeutic vaccines and drugs is discussed.

Tài liệu tham khảo

Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, Town T, Jones C, von Andrian UH, Freeman GJ, Sharpe AH, BenMohamed L, Ahmed R, Wechsler SL, Ghiasi H (2011) The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol 85:4184–97

Allen SJ, Rhode-Kurnow A, Mott KR, Jiang X, Carpenter D, Rodriguez-Barbosa JI, Jones C, Wechsler SL, Ware CF, Ghiasi H (2014) Interactions between Herpesvirus entry mediator (TNFRSF14) and latency-associated transcript during herpes simplex virus 1 latency. J Virol 88:1961–1971

Blyth WA, Harbour DA, Hill TJ (1980) Effect of immunosuppression on recurrent herpes simplex in mice. Infect Immun 29:902–907

Chentoufi AA, BenMohamed L (2012) Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol 2012:149135

Chentoufi AA, Dervillez X, Dasgupta G, Nguyen C, Kabbara KW, Jiang X, Nesburn AB, Wechsler SL, BenMohamed L (2012) The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells. Viral Immunol.

Chentoufi AA, Kritzer E, Tran MV, Dasgupta G, Lim CH, Yu DC, Afifi RE, Jiang X, Carpenter D, Osorio N, Hsiang C, Nesburn AB, Wechsler SL, BenMohamed L (2011) The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. J Virol 85:9127–9138

Cook SD, Paveloff MJ, Doucet JJ, Cottingham AJ, Sedarati F, Hill JM (1991) Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest Ophthalmol Vis Sci 32:1558–1561

Deatly AM, Spivack JG, Lavi E, Fraser NW (1987) RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc Natl Acad Sci U S A 84:3204–3208

Deshmane SL, Nicosia M, Valyi-Nagy T, Feldman LT, Dillner A, Fraser NW (1993) An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation. Virology 196:868–872

Devi-Rao GB, Bloom DC, Stevens JG, Wagner EK (1994) Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia. J Virol 68:1271–1282

Farooq AV, Shukla D (2012) Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 57:448–462

Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP (2002) Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 99:978–983

Gebhardt BM, Halford WP (2005) Evidence that spontaneous reactivation of herpes virus does not occur in mice. Virol J 2:67

Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL (1992) Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Virology 190:233–239

Halford WP, Gebhardt BM, Carr DJ (1996) Mechanisms of herpes simplex virus type 1 reactivation. J Virol 70:5051–5060

Harbour DA, Hill TJ, Blyth WA (1981) Acute and recurrent herpes simplex in several strains of mice. J Gen Virol 55:31–40

HEDS (1998) Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic eye disease study group. N Engl J Med 339:300–306

Higaki S, Gebhardt B, Lukiw W, Thompson H, Hill J (2003) Gene expression profiling in the HSV-1 latently infected mouse trigeminal ganglia following hyperthermic stress. Curr Eye Res 26:231–8

Higaki S, Gebhardt BM, Lukiw WJ, Thompson HW, Hill JM (2002) Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Invest Ophthalmol Vis Sci 43:1862–9

Hill JM, Sedarati F, Javier RT, Wagner EK, Stevens JG (1990) Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology 174:117–125

Hill TJ, Blyth WA, Harbour DA (1982) Recurrent herpes simplex in mice; topical treatment with acyclovir cream. Antiviral Res 2:135–46

Himmelein S, St Leger AJ, Knickelbein JE, Rowe A, Freeman ML, Hendricks RL (2011) Circulating herpes simplex type 1 (HSV-1)-specific CD8+ T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae 2:5

Inman M, Perng G, Henderson G, Ghiasi H, Nesburn A, Wechsler S, Jones C (2001) Region of herpes simplex virus type 1 latency-associated transcript sufficient for wild type spontaneous reactivation promotes cell survival in tissue culture. J Virol 75:3636–3646

Jiang X, Chentoufi AA, Hsiang C, Carpenter D, Osorio N, BenMohamed L, Fraser NW, Jones C, Wechsler SL (2011) The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing. J Virol 85:2325–2332

Jin L, Carpenter D, Moerdyk-Schauwecker M, Vanarsdall AL, Osorio N, Hsiang C, Jones C, Wechsler SL (2008) Cellular FLIP can substitute for the herpes simplex virus type 1 latency-associated transcript gene to support a wild-type virus reactivation phenotype in mice. J Neurovirol 14:389–400

Jin L, Perng GC, Carpenter D, Mott KR, Osorio N, Naito J, Brick DJ, Jones C, Wechsler SL (2007) Reactivation phenotype in rabbits of a herpes simplex virus type 1 mutant containing an unrelated antiapoptosis gene in place of latency-associated transcript. J Neurovirol 13:78–84

Jin L, Perng GC, Mott KR, Osorio N, Naito J, Brick DJ, Carpenter D, Jones C, Wechsler SL (2005) A herpes simplex virus type 1 mutant expressing a baculovirus inhibitor of apoptosis gene in place of latency-associated transcript has a wild-type reactivation phenotype in the mouse. J Virol 79:12286–12295

Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM (2005) HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 46:241–247

Keadle TL, Alexander DE, Leib DA, Stuart PM (2008) Interferon gamma is not required for recurrent herpetic stromal keratitis. Virology 380:46–51

Keadle TL, Laycock KA, Miller JK, Hook KK, Fenoglio ED, Francotte M, Slaoui M, Stuart PM, Pepose JS (1997) Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J Infect Dis 176:331–338

Keadle TL, Laycock KA, Morris JL, Leib DA, Morrison LA, Pepose JS, Stuart PM (2002a) Therapeutic vaccination with vhs(-) herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J Gen Virol 83:2361–2365

Keadle TL, Morris JL, Pepose JS, Stuart PM (2002b) CD4(+) and CD8(+) cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb Pathog 32:255–262

Keadle TL, Morris JL, Stuart PM (2005) The effects of aminoguanidine on primary and recurrent ocular herpes simplex virus infection. Nitric Oxide 13:247–253

Keadle TL, Morrison LA, Morris JL, Pepose JS, Stuart PM (2002c) Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol 76:3615–3625

Keadle TL, Usui N, Laycock KA, Kumano Y, Pepose JS, Stuart PM (2001) Cytokine expression in murine corneas during recurrent herpetic stromal keratitis. Ocul Immunol Inflamm 9:193–205

Keadle TL, Usui N, Laycock KA, Miller JK, Pepose JS, Stuart PM (2000) IL-1 and TNF-alpha are important factors in the pathogenesis of murine recurrent herpetic stromal keratitis. Invest Ophthalmol Vis Sci 41:96–102

Khan AA, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, Lopes PP, Pham TT, Hewett C, Kuang J, Ong N, Huang L, Scarfone VM, Nesburn AB, Wechsler SL, BenMohamed L (2015) Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from ocular herpes symptomatic and asymptomatic individuals. J Virol. doi:10.1128/JVI.03419-14

Kumar M, Hill JM, Clement C, Varnell ED, Thompson HW, Kaufman HE (2009) A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest Ophthalmol Vis Sci 50:5601–5608

Kumaraguru U, Davis I, Rouse BT (1999) Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. J Neurovirol 5:42–47

Kuo T, Wang C, Badakhshan T, Chilukuri S, BenMohamed L (2014) The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine 32:6733–6745

Laycock KA, Brady RH, Lee SF, Osborne PA, Johnson EM, Pepose JS (1994) The role of nerve growth factor in modulating herpes simplex virus reactivation in vivo. Graefes Arch Clin Exp Ophthalmol 232:421–425

Laycock KA, Lee SF, Brady RH, Pepose JS (1991) Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci 32:2741–2746

Laycock KA, Lee SF, Stulting RD, Croen KD, Ostrove JM, Straus SE, Pepose JS (1993) Herpes simplex virus type 1 transcription is not detectable in quiescent human stromal keratitis by in situ hybridization. Invest Ophthalmol Vis Sci 34:285–292

Leib DA, Bogard CL, Kosz-Vnenchak M, Hicks KA, Coen DM, Knipe DM, Schaffer PA (1989) A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J Virol 63:2893–2900

Loutsch JM, Perng GC, Hill JM, Zheng X, Marquart ME, Block TM, Ghiasi H, Nesburn AB, Wechsler SL (1999) Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J Virol 73:767–771

Maggioncalda J, Mehta A, Bagasra O, Fraser NW, Block TM (1996) A herpes simplex virus type 1 mutant with a deletion immediately upstream of the LAT locus establishes latency and reactivates from latently infected mice with normal kinetics. J Neurovirol 2:268–278

Maggioncalda J, Mehta A, Fraser NW, Block TM (1994) Analysis of a herpes simplex virus type 1 LAT mutant with a deletion between the putative promoter and the 5′ end of the 2.0-kilobase transcript. J Virol 68:7816–7824

Margolis TP, Elfman FL, Leib D, Pakpour N, Apakupakul K, Imai Y, Voytek C (2007) Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J Virol 81:11069–11074

Meyers RL (1975) Immunology of herpes simplex virus infection. Int Ophthalmol Clin 15:37–47

Morris J, Stuart PM, Rogge M, Potter C, Gupta N, Yin XT (2012a) Recurrent herpetic stromal keratitis in mice, a model for studying human HSK. J Vis Exp: e4276.

Morris JE, Zobell S, Yin XT, Zakeri H, Summers BC, Leib DA, Stuart PM (2012b) Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1. J Immunol 188:793–799

Nesburn AB (1983) Report of the corneal disease panel: Vision research: a national plan 1983-1987. Vol II, Part III. C.V. Mosby Co, St. Louis

Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL (1998a) Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 252:200–209

Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL (1998b) A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci 39:1163–1170

Neumann DM, Bhattacharjee PS, Giordani NV, Bloom DC, Hill JM (2007) In vivo changes in the patterns of chromatin structure associated with the latent herpes simplex virus type 1 genome in mouse trigeminal ganglia can be detected at early times after butyrate treatment. J Virol 81:13248–53

Peng W, Henderson G, Inman M, BenMohamed L, Perng GC, Wechsler SL, Jones C (2005) The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice. J Virol 79:6162–6171

Pepose JS, Laycock KA, Miller JK, Chansue E, Lenze EJ, Gans LA, Smith ME (1992) Reactivation of latent herpes simplex virus by excimer laser photokeratectomy. Am J Ophthalmol 114:45–50

Perng G, Jones C, Ciacci-Zanella H, Henderson G, Yukht A, Slanina S, Hofman F, Ghiasi H, Nesburn A, Wechsler S (2000) Virus induced neuronal apoptosis blocked by the herpes simplex virus latency associated transcript (LAT). Science 287:1500–1503

Perng GC, Dunkel EC, Geary PA, Slanina SM, Ghiasi H, Kaiwar R, Nesburn AB, Wechsler SL (1994) The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol 68:8045–8055

Perng GC, Maguen B, Jin L, Mott KR, Osorio N, Slanina SM, Yukht A, Ghiasi H, Nesburn AB, Inman M, Henderson G, Jones C, Wechsler SL (2002) A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J Virol 76:1224–1235

Perng GC, Slanina SM, Ghiasi H, Nesburn AB, Wechsler SL (2001) The effect of latency-associated transcript on the herpes simplex virus type 1 latency-reactivation phenotype is mouse strain-dependent. J Gen Virol 82:1117–1122

Rock DL, Nesburn AB, Ghiasi H, Ong J, Lewis TL, Lokensgard JR, Wechsler SL (1987) Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol 61:3820–3826

Rowe AM, St Leger AJ, Jeon S, Dhaliwal DK, Knickelbein JE, Hendricks RL (2013) Herpes keratitis. Prog Retin Eye Res 32:88–101

Sawtell NM, Thompson RL (1992) Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol 66:2150–2156

Schacker T, Zeh J, Hu HL, Hill E, Corey L (1998) Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 178:1616–1622

Shimeld C, Hill T, Blyth B, Easty D (1989) An improved model of recurrent herpetic eye disease in mice. Curr Eye Res 8:1193–1205

Shimeld C, Hill TJ, Blyth WA, Easty DL (1990) Reactivation of latent infection and induction of recurrent herpetic eye disease in mice. J Gen Virol 71(Pt 2):397–404

Shimeld C, Whiteland JL, Nicholls SM, Easty DL, Hill TJ (1996a) Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease. J Gen Virol 77(Pt 5):977–85

Shimeld C, Whiteland JL, Nicholls SM, Grinfeld E, Easty DL, Gao H, Hill TJ (1995) Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. J Neuroimmunol 61:7–16

Shimeld C, Whiteland JL, Williams NA, Easty DL, Hill TJ (1996b) Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and immune cell infiltration. J Gen Virol 77(Pt 10):2583–90

Shimeld C, Whiteland JL, Williams NA, Easty DL, Hill TJ (1997) Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1. J Gen Virol 78(Pt 12):3317–25

Smith RE, McDonald HR, Nesburn AB, Minckler DS (1980) Penetrating keratoplasty: changing indications, 1947 to 1978. Arch Ophthalmol 98:1226–1229

Spivack JG, Fareed MU, Valyi-Nagy T, Nash TC, JS OK, Gesser RM, McKie EA, MacLean AR, Fraser NW, Brown SM (1995) Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J Gen Virol 76:321–332

Spivack JG, Fraser NW (1987) Detection of herpes simplex virus type 1 transcripts during latent infection in mice. J Virol 61:3841–3847

Spivack JG, Fraser NW (1988a) Expression of herpes simplex virus type 1 (HSV-1) latency-associated transcripts and transcripts affected by the deletion in avirulent mutant HFEM: evidence for a new class of HSV-1 genes. J Virol 62:3281–3287

Spivack JG, Fraser NW (1988b) Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. J Virol 62:1479–1485

Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT (1987) RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science 235:1056–1059

Stroop WG, Rock DL, Fraser NW (1984) Localization of herpes simplex virus in the trigeminal and olfactory systems of the mouse central nervous system during acute and latent infections by in situ hybridization. Lab Investig 51:27–38

Stuart PM, Keadle TL (2012a) Recurrent herpetic stromal keratitis in mice: a model for studying human HSK. Clin Dev Immunol 2012:728480

Stuart PM, Keadle TL (2012b) Recurrent herpetic stromal keratitis in mice: a model for studying human HSK. Clin Dev Immunol 88:72–78

Stuart PM, Morris JE, Sidhu M, Keadle TL (2008) CCL3 protects mice from corneal pathology during recurrent HSV-1 infection. Front Biosci 13

Stuart PM, Summers B, Morris JE, Morrison LA, Leib DA (2004) CD8(+) T cells control corneal disease following ocular infection with herpes simplex virus type 1. J Gen Virol 8:2055–63

Toma HS, Murina AT, Areaux RG Jr, Neumann DM, Bhattacharjee PS, Foster TP, Kaufman HE, Hill JM (2008) Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol 23:249–73

Trousdale MD, Steiner I, Spivack JG, Deshmane SL, Brown SM, MacLean AR, Subak-Sharpe JH, Fraser NW (1991) In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. J Virol 65:6989–6993

Wald A, Zeh J, Selke S, Ashley RL, Corey L (1995) Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 333:770–775

Walker J, Laycock KA, Pepose JS, Leib DA (1998) Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice. Vaccine 16:6–8

Webre JM, Hill JM, Nolan NM, Clement C, McFerrin HE, Bhattacharjee PS, Hsia V, Neumann DM, Foster TP, Lukiw WJ, Thompson HW (2012) Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases. J Biomed Biotechnol 2012:612316

West DM, Del Rosso CR, Yin XT, Stuart PM (2014) CXCL1 but not IL-6 is required for recurrent herpetic stromal keratitis. J Immunol 192:1762–1767

Xu F, Schillinger JA, Sternberg MR, Johnson RE, Lee FK, Nahmias AJ, Markowitz LE (2002) Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 185:1019–1024

Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–973

Zlotnik I, Smith CE, Grant DP, Peacock S (1970) The effect of immunosuppression on viral encephalitis, with special reference to cyclophosphamide. Br J Exp Pathol 51:434–9

Zwaagstra J, Ghiasi H, Nesburn AB, Wechsler SL (1989) In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1. J Gen Virol 70:2163–2169

Zwaagstra JC, Ghiasi H, Slanina SM, Nesburn AB, Wheatley SC, Lillycrop K, Wood J, Latchman DS, Patel K, Wechsler SL (1990) Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol 64:5019–5028

Thông tin
Thông tin xuất bản

Journal of NeuroVirology

Tập 21

508-517

Thông tin tác giả